By Kelly Cloonan
Shares of Portage Biotech climbed after the company reported confirmatory data for its PORT-7 treatment of mesothelioma, supporting plans for a human trial.
The stock rose 21% to $10.23 Monday. Shares have more than doubled over the past 12 months.
The clinical stage immuno-oncology company said Monday its PORT-7, a selective adenosine A2B receptor inhibitor, demonstrated superior single agent activity compared with treatment with single agent anti-PD1 antibody in a murine model.
Combining both PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone, showing favorable immune response and increases in immune effector cells for mice in the trial, the company said.
The treatment is targeted at mesothelioma, an aggressive cancer with limited treatment options.
Portage is now making preparations to begin a first-in-human clinical trial with PORT-7, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 28, 2025 13:20 ET (17:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.